ABT

Abbott Laboratories

Compare

Market cap	$190.11B
Enterprise value	$191.85B

Revenue	$40.326B
EBITDA	$8.302B
Income	$5.630B
Revenue Q/Q	2.23%
Revenue Y/Y	-2.84%

P/E	31.62
Forward P/E	21.91
EV/Sales	4.76
EV/EBITDA	23.11
EV/EBIT	26.78
PEG	18.23
Price/Sales	4.71
P/FCF	38.62
Price/Book	4.90
Book/Share	20.86
Cash/Share	3.91
FCF yield	2.59%

Employees	107,000
RPE	$376.879k

Volume	4.066M / 7.982M
Relative vol.	0.51 ×

EPS	3.23
EPS Q/Q	-17.86%
Est. EPS Q/Q	-31.06%

Profit margin	14.27%
Oper. margin	15.76%
Gross margin	55.18%
EBIT margin	17.76%
EBITDA margin	20.59%

Ret. on assets	7.74%
Ret. on equity	14.72%
ROIC	9.89%
ROCE	12.26%

Debt/Equity	0.89
Net debt/EBITDA	3.92
Current ratio	1.60
Quick ratio	1.11

Volatility	1.69%
Beta	0.38

RSI	40.94

Range	$101.94 – $103.85
52 weeks	$89.67 – $121.64
SMA 50	$104 -1.94%
SMA 200	$110 -7.79%

1 year target	$120 +17.81%
Mean Recomm.	1.76

Insider ownership	0.73%
Inst. ownership	75.68%

Shares outst.	1.740B
Shares float	0.000 0.00%
Short % of float	0.82%
Short ratio	2.49

1 year target	$120 +17.81%
Mean Recomm.	1.76

Dividend	$2.12
Dividend yield	2.04%
Payout ratio	65.63%
Payment date	15 Aug 2024
Ex-dividend date	15 Jul 2024
Earnings date	18 Jul 2024

IPO year	1978
Country	United States

Compare with other stocks

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

Recent Abbott Laboratories news

Filter

Monday, 17 June 2024
barrons	New Weight-Loss Drugs and Devices Are Coming This Week
Thursday, 6 June 2024
msn	Is Abbott Laboratories the Best Value Dividend Aristocrat Stock?
Friday, 31 May 2024
insidermonkey	The Most Profitable Biotechnology Company in the World
Thursday, 9 May 2024
reuters	Drugmaker Abbott India posts Q4 profit rise on higher sales
Wednesday, 8 May 2024
gurufocus	Insider Sale: Executive Vice President Lisa Earnhardt Sells 22,852 Shares of Abbott ...
Monday, 6 May 2024
insidermonkey	11 Best Recession Dividend Stocks To Buy
Saturday, 13 April 2024
msn	Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
Friday, 12 April 2024
investors	Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Thursday, 11 April 2024
gurufocus	Abbott Laboratories's Dividend Analysis
Tuesday, 26 March 2024
insidermonkey	25 Countries with the Highest Death Rate From Malnutrition
yahoo	25 Countries with Lowest Rates of Infant Mortality
Monday, 25 March 2024
investingchannel	30 Countries with Highest Proportion of Older Adults
Sunday, 24 March 2024
insidermonkey	16 Most Undervalued Large Cap Stocks To Buy According To Analysts
insidermonkey	14 Best Medical Device Stocks To Buy Now
Friday, 22 March 2024
msn	15 Highest Paying Countries for Biomedical Engineers
Thursday, 21 March 2024
insidermonkey	11 Best Healthcare ETFs To Buy Now
Thursday, 14 March 2024
insidermonkey	20 Countries That Spend the Most on Healthcare
Monday, 11 March 2024
msn	UPDATE 1-Walgreens settles New York charges it grossly inflated prices of infant formula
Wednesday, 6 March 2024
investors	Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
Wednesday, 28 February 2024
insidermonkey	25 Healthiest Countries in the World
Wednesday, 21 February 2024
insidermonkey	15 Best Least Shorted Stocks to Buy Now
Tuesday, 20 February 2024
insidermonkey	20 Most Sustainable Companies in the US
Wednesday, 14 February 2024
insidermonkey	15 States with the Best Healthcare in the US
Saturday, 10 February 2024
insidermonkey	30 Most Valuable Drug Companies in 2024

Wednesday, 7 February 2024
investors	Abbott Laboratories Stock Getting Closer To Key Technical Benchmark
Saturday, 3 February 2024
reuters	UPDATE 1-Abbott Labs must face lawsuit over PediaSure height claims
Friday, 2 February 2024
reuters	Abbott Labs must face lawsuit over PediaSure height claims
Thursday, 1 February 2024
yahoo	Executive Vice President Andrea Wainer Sells 42,500 Shares of Abbott Laboratories
zacks	Top Research Reports for Abbott, T-Mobile & Booking
insidermonkey	15 Highest Quality Creatine Supplements of 2024
Wednesday, 31 January 2024
msn	LLY, ABT, CVS: Which Healthcare Stock Do Analysts Prefer?
barrons	Abbott Rolls Out Protein Shake Amid Weight Loss Drug Craze
reuters	Abbott launches protein shake brand to help people on weight-loss drug
Friday, 26 January 2024
insidermonkey	15 Fastest Growing States in the US
Thursday, 25 January 2024
insidermonkey	Abbott Laboratories Q4 2023 Earnings Call Transcript
Wednesday, 24 January 2024
investors	Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat
Saturday, 20 January 2024
insidermonkey	Retirement Stock Portfolio: 12 Healthcare Stocks To Consider
Monday, 15 January 2024
zacks	Top Analyst Reports for AMD, Abbott Laboratories & QUALCOMM
Friday, 5 January 2024
insidermonkey	10 Best January Dividend Stocks To Buy
Tuesday, 2 January 2024
barrons	Baby Formula Recall Hits Shelves. What to Know.
Thursday, 28 December 2023
zacks	Brokers Suggest Investing in Abbott : Read This Before Placing a Bet
Tuesday, 19 December 2023
msn	Here's Why Abbott Gained But Lagged the Market Today
Monday, 18 December 2023
zacks	Abbott Gains From Global Expansion Amid Macro Woes
Thursday, 14 December 2023
yahoo	Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets
Sunday, 10 December 2023
insidermonkey	12 Healthcare Stocks Billionaires Like the Most
Friday, 8 December 2023
fool	2 Healthcare Stocks to Buy Hand Over Fist in December
Thursday, 7 December 2023
yahoo	Is Abbott Laboratories' Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Tuesday, 5 December 2023
yahoo	12 Best Healthcare Dividend Stocks To Buy Now
Thursday, 30 November 2023
zacks	Abbott Rises Higher Than Market: Key Facts
Sunday, 26 November 2023
insidermonkey	15 Best Drug Stocks To Invest In
insidermonkey	12 Best Medical Technology Stocks To Buy Now

Filter news

Notable SEC filings of Abbott Laboratories

All filings Last yearly filing Filter


10-Q 2 May 2024	Quarterly report
8-K 1 May 2024	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 29 Apr 2024	Submission of Matters to a Vote of Security Holders
8-K 17 Apr 2024	Results of Operations and Financial Condition; Financial Statements and Exhibits
10-K 16 Feb 2024	Yearly report
8-K 29 Jan 2024	Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Creation of a D...
8-K 24 Jan 2024	Results of Operations and Financial Condition; Financial Statements and Exhibits
10-Q 1 Nov 2023	Quarterly report
8-K 18 Oct 2023	Results of Operations and Financial Condition; Financial Statements and Exhibits
10-Q 3 Aug 2023	Quarterly report
8-K 20 Jul 2023	Results of Operations and Financial Condition; Financial Statements and Exhibits

All SEC filings Last yearly filing Filter filings

Recent insiders trading at Abbott Laboratories

Filter

Insider	Trans. Transaction	Price per share	Total value
Jr. Robert E. Funck, Executive Vice President	Option 10 May 2024	$47.00	$474,559
Lisa D Earnhardt Executive Vice President	Sale 7 May 2024	$106.25	$2,428,025
Daniel Gesua Sive Salvadori Executive Vice President	Sale 29 Feb 2024	$118.50	$114,116
Louis H. Morrone Executive Vice President	Sale 29 Feb 2024	$118.50	$94,919
Mary K Moreland Executive Vice President	Sale 29 Feb 2024	$118.50	$80,106
John A. Jr. Mccoy VICE PRESIDENT	Sale 29 Feb 2024	$118.50	$55,932
Lisa D Earnhardt Executive Vice President	Sale 29 Feb 2024	$118.50	$82,239
Hubert L Allen Executive Vice President	Sale 29 Feb 2024	$118.50	$101,081
Andrea F Wainer Executive Vice President	Option 23 Feb 2024	$59.94	$749,250
Andrea F Wainer Executive Vice President	Option 29 Jan 2024	$50.80	$2,159,000
Andrea F Wainer Executive Vice President	Option 14 Dec 2023	$44.40	$666,000

Filter insiders trades All insiders trades

Recent call transcripts of Abbott Laboratories

Q2 2022 20 July 2022	Q2 2022 Earnings Call Transcript
Q1 2022 20 April 2022	Q1 2022 Earnings Call Transcript
Q4 2021 26 January 2022	Q4 2021 Earnings Call Transcript
Q3 2021 20 October 2021	Q3 2021 Earnings Call Transcript
Q2 2021 22 July 2021	Q2 2021 Earnings Call Transcript
Q1 2021 20 April 2021	Q1 2021 Earnings Call Transcript
Q4 2020 27 January 2021	Q4 2020 Earnings Call Transcript
Q1 2020 16 April 2020	Q1 2020 Earnings Call Transcript
Q4 2019 22 January 2020	Q4 2019 Earnings Call Transcript
Q3 2019 16 October 2019	Q3 2019 Earnings Call Transcript
Q2 2019 17 July 2019	CEO Miles White on Q2 2019 Results - Earnings Call Transcript

All call transcripts

29,175 people own Abbott Laboratories on Robinhood

Overall analyst rating

Price target

Current $102.12

Average $120.31

Low $107 High $130

Dividends

Ex-dividend date	15 Jul 2024	Frequency	Quarterly	Annual dividend	+8.51%
Next dividend	15 Aug 2024	Dividend yield	2.04%	Growth period	10 years
Last dividend date		Yield 3 years	1.87%	Growth 3 years	+12.31%
Last dividend		Yield 5 years	1.64%	Growth 5 years	+12.74%

Abbott Laboratories dividend history

Abbott Laboratories executives

Insider	Age	Since	Compensation
Miles White (65) Executive Chairman of the Board since 2020	65	2020	$27,802,800
Robert Ford (46) President, Chief Executive Officer, and Director since 2020	46	2020	$11,897,900
Lisa Earnhardt (50) Executive Vice President - Medical Devices since 2019	50	2019	$7,478,840
Hubert Allen (54) Executive Vice President, General Counsel, and Secretary since 2013	54	2013	$7,317,780
Miles D. White M.B.A. (65) Exec. Chairman	65		$6,970,034
Daniel Salvadori (41) Executive Vice President - Nutritional Products since 2017	41	2017	$6,767,810
Robert B. Ford (47) Chairman, Pres, and CEO	47		$5,051,334
John Capek (58) Executive Vice President - Ventures since 2015	58	2015	$3,765,920
Robert E. Funck Jr. (60) Exec. VP of Fin. and CFO	60		$2,430,522
Hubert L. Allen (55) Exec. VP, Gen. Counsel, and Sec.	55		$1,823,642
Daniel Gesua Sive Salvadori (42) Exec. VP, Group Pres of Established Pharmaceuticals, and Nutritional Products	42		$1,694,921
John F. Ginascol (62) Exec. VP of Core Diagnostics	62		$1,678,298
Robert Alpern (69) Independent Director since 2008	69	2008	$390,233
Sally Blount (58) Independent Director since 2011	58	2011	$336,265
Glenn Tilton (71) Independent Director since 2007	71	2007	$331,910
Samuel Scott (75) Independent Director since 2007	75	2007	$331,910
William Osborn (72) Lead Independent Director since 2013	72	2013	$330,910
Roxanne Austin (59) Independent Director since 2000	59	2000	$326,910
Edward Liddy (73) Independent Director since 2010	73	2010	$325,910
Phebe Novakovic (62) Independent Director since 2010	62	2010	$315,910
Nancy McKinstry (61) Independent Director since 2011	61	2011	$306,910
Michelle Kumbier (52) Independent Director since 2018	52	2018	$306,910
John Stratton (59) Independent Director since 2017	59	2017	$300,910
Daniel Starks (65) Independent Director since 2017	65	2017	$300,910
Darren McDew (59) Independent Director since 2019	59	2019	$31,500
Randel Woodgrift (58) Senior Vice President - CRM since 2019	58	2019
Alejandro Wellisch (45) Senior Vice President - Established Pharmaceuticals and Latin America since 2017	45	2017
Jared Watkin (52) Senior Vice President - Diabetes Care since 2015	52	2015
Christopher Scoggins (50) Senior Vice President - Rapid Diagnostics since 2019	50	2019
Michael Pederson (58) Senior Vice President - Electrophysiology and Heart Failure since 2019	58	2019
Joseph Manning (51) Senior Vice President - Nutrition International since 2017	51	2017
Sammy Karam (58) Senior Vice President - Established Pharmaceuticals and Emerging Markets since 2019	58	2019
Michael Dale (60) Senior Vice President - Structural Heart since 2019	60	2019
Jaime Contreras (63) Senior Vice President - Core Laboratory Diagnostics and Commercial Operations since 2013	63	2013
Charles Brynelsen (63) Senior Vice President - Abbott Vascular since 2017	63	2017
Roger Bird (63) Senior Vice President - U.S. Nutrition since 2015	63	2015
Andrea Wainer (51) Executive Vice President - Rapid and Molecular Diagnostics since 2019	51	2019
Andrew Lane (49) Executive Vice President - Established Pharmaceuticals since 2017	49	2017
John Ginascol (61) Executive Vice President - Core Diagnostics since 2019	61	2019
Mary Moreland (53) Executive Vice President of Human Resources since 2019	53	2019
Robert Funck (58) Chief Financial Officer and Executive Vice President - Finance since 2020	58	2020
Gregory A. Ahlberg (53) Sr. VP of Core Laboratory Diagnostics and Commercial Operations	53
Elaine R. Leavenworth (62) Sr. VP, Chief Marketing, and External Affairs Officer	62
Melissa Brotz
James E. Young
Scott Michael Leinenweber (49) VP of Investor Relations, Licensing, and Acquisitions	49

Comparable companies

Compare more metrics Compare with other companies

Company	Market cap	P/E	EV/EBITDA	P/S	P/B	P/FCF	Change
ABT Abbott Laboratories	$190.11B	31.62	23.11	4.71	4.90	38.62	-1.83%
JNJ Johnson & Johnson	$459.47B	9.53	12.66	5.62	6.68	24.57	-0.68%
PFE Pfizer Inc.	$291.64B	N/A	28.95	5.29	3.28	57.12	-0.43%
RHHBY Roche Holding AG	$280.28B	21.37	11.78	4.02	9.45	15.03	-0.56%
AZN Astrazeneca plc	$215.24B	94.06	21.45	4.70	5.50	32.78	-0.27%
TMO Thermo Fisher Scientific Inc.	$210.98B	34.27	22.78	4.97	4.51	27.60	-0.71%
NVS Novartis AG	$203.64B	21.15	12.27	4.47	4.36	19.72	-0.06%
BMY Bristol-Myers Squibb Co.	$167.61B	N/A	7.85	3.68	5.70	13.40	+0.83%
MDT Medtronic Plc	$104.80B	27.74	15.51	3.24	2.09	20.15	-0.99%
BSX Boston Scientific Corp.	$65.88B	63.43	36.40	4.48	3.42	38.12	-0.38%
HOLX Hologic, Inc.	$18.61B	38.03	15.76	4.70	3.71	19.61	+0.58%

Compare more metrics Compare with other companies

Abbott Laboratories abbott.com/

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.

Health Care > Health Care Equipment
Abbott Laboratories, 100 Abbott Park Road, North Chicago 60064-6400, United States
224 667 6100
Investor relations

Dividends

Ex-dividend date	15 Jul 2024	Frequency	Quarterly	Annual dividend	+8.51%
Next dividend	15 Aug 2024	Dividend yield	2.04%	Growth period	10 years
Last dividend date		Yield 3 years	1.87%	Growth 3 years	+12.31%
Last dividend		Yield 5 years	1.64%	Growth 5 years	+12.74%

Abbott Laboratories dividend history

Quarterly EPS estimates

Quarterly
Annual

Profit margin

Quarterly
Annual

Debt to assets

Quarterly
Annual

Cash flow

Quarterly
Annual

Balance sheet

Quarterly
Annual

XSLX

(in millions USD)	31 Mar 2024	31 Dec 2023	30 Sep 2023	30 Jun 2023
Current assets
Cash	$6,284	$7,279	$6,709	$7,835
Short term investments	$367		$338	$320
Net receivables	$6,605	$6,565	$6,499	$6,172
Inventory	$6,827	$6,570	$6,650	$6,871
Total current assets	$22,376	$22,670	$22,664	$23,505
Long term investments	$818	$799	$788	$799
Property, plant & equipment	$10,107	$10,154	$9,552	$9,449
Goodwill & intangible assets	$31,679	$32,494	$32,559	$33,092
Total noncurrent assets	$50,091	$50,544	$49,426	$49,849
Total investments	$1,185	$799	$1,126	$1,119
Total assets	$72,467	$73,214	$72,090	$73,354
Current liabilities
Accounts payable	$4,178	$4,295	$3,961	$4,211
Deferred revenue
Short long term debt	$2,010	$1,080	$1,051	$2,284
Total current liabilities	$14,021	$13,841	$13,042	$14,350
Long term debt	$12,576	$13,599	$14,477	$14,562
Total noncurrent liabilities	$19,403	$20,546	$21,354	$21,600
Total debt	$14,586	$14,679	$15,528	$16,846
Total liabilities	$33,424	$34,387	$34,396	$35,950
Stockholders' equity
Retained earnings	$38,011	$37,554	$36,920	$36,355
Other stockholder equity	-$8,166	-$7,839	-$8,480	-$8,071
Total stockholder equity	$39,043	$38,827	$37,694	$37,404

(in millions USD)	2023	2022	2021
Current assets
Cash	$7,279	$10,170	$10,249
Short term investments
Net receivables	$6,565	$6,218	$6,487
Inventory	$6,570	$6,173	$5,157
Total current assets	$22,670	$25,224	$24,239
Long term investments	$799	$766	$816
Property, plant & equipment	$10,154	$9,162	$8,959
Goodwill & intangible assets	$32,494	$33,253	$35,970
Total noncurrent assets	$50,544	$49,214	$50,957
Total investments	$799	$766	$816
Total assets	$73,214	$74,438	$75,196
Current liabilities
Accounts payable	$4,295	$4,607	$4,408
Deferred revenue
Short long term debt	$1,080	$2,251	$754
Total current liabilities	$13,841	$15,489	$13,105
Long term debt	$13,599	$14,522	$17,296
Total noncurrent liabilities	$20,546	$22,044	$26,067
Total debt	$14,679	$16,773	$18,050
Total liabilities	$34,387	$37,533	$39,172
Stockholders' equity
Retained earnings	$37,554	$35,257	$31,528
Other stockholder equity	-$7,839	-$8,051	-$8,374
Total stockholder equity	$38,827	$36,905	$36,024

Income statement

Quarterly
Annual

XSLX

(in millions USD)	31 Mar 2024	31 Dec 2023	30 Sep 2023	30 Jun 2023
Revenue
Total revenue	$9,964	$10,241	$10,143	$9,978
Cost of revenue	$4,463	$4,556	$4,605	$4,483
Gross profit	$5,501	$5,685	$5,538	$5,495
Operating activities
Research & development	$684	$700	$672	$715
Selling, general & administrative	$2,959	$2,724	$2,723	$2,740
Total operating expenses	$4,115	$3,905	$3,891	$3,953
Operating income	$1,386	$1,780	$1,647	$1,542
Income from continuing operations
EBIT	$1,577	$1,954	$1,837	$1,795
Income tax expense	$211	$201	$235	$261
Interest expense	$141	$159	$166	$159
Net income
Net income	$1,225	$1,594	$1,436	$1,375
Income (for common shares)	$1,225	$1,594	$1,436	$1,375

(in millions USD)	2023	2022	2021
Revenue
Total revenue	$40,109	$43,653	$43,075
Cost of revenue	$17,975	$19,142	$18,537
Gross profit	$22,134	$24,511	$24,538
Operating activities
Research & development	$2,741	$2,888	$2,742
Selling, general & administrative	$10,949	$11,248	$11,324
Total operating expenses	$15,656	$16,149	$16,113
Operating income	$6,478	$8,362	$8,425
Income from continuing operations
EBIT	$7,301	$8,864	$8,744
Income tax expense	$941	$1,373	$1,140
Interest expense	$637	$558	$533
Net income
Net income	$5,723	$6,933	$7,071
Income (for common shares)	$5,723	$6,933	$7,071

Cash flows

Quarterly
Annual

XSLX

(in millions USD)	31 Mar 2024	31 Dec 2023	30 Sep 2023	30 Jun 2023
Net income	$1,225	$1,594	$1,436	$1,375
Operating activities
Depreciation	$805	$813	$824	$800
Business acquisitions & disposals			-$51	-$786
Stock-based compensation	$304	$114	$117	$132
Total cash flows from operations	$1,025	$3,038	$1,877	$1,203
Investing activities
Capital expenditures	-$398	-$755	-$560	-$507
Investments	-$28	-$71	-$38	$79
Total cash flows from investing	-$425	-$824	-$634	-$1,213
Financing activities
Dividends paid	-$957	-$888	-$888	-$890
Sale and purchase of stock	-$92	-$225	$54	-$411
Net borrowings	-$127	-$939	-$1,506	$12
Total cash flows from financing	-$1,176	-$2,052	-$2,340	-$1,289
Effect of exchange rate	-$36	$25	-$29	-$27
Change in cash and equivalents	-$612	$187	-$1,126	-$1,326

(in millions USD)	2023	2022	2021
Net income	$5,723	$6,933	$7,071
Operating activities
Depreciation	$3,243	$3,267	$3,538
Business acquisitions & disposals	-$837	$48	-$53
Stock-based compensation	$644	$685	$640
Total cash flows from operations	$7,261	$9,581	$10,533
Investing activities
Capital expenditures	-$2,202	-$1,777	-$1,885
Investments	-$116	-$33	-$96
Total cash flows from investing	-$3,133	-$1,740	-$2,008
Financing activities
Dividends paid	-$3,556	-$3,309	-$3,202
Sale and purchase of stock	-$1,060	-$3,628	-$2,044
Net borrowings	-$2,475	-$699	-$248
Total cash flows from financing	-$7,091	-$7,636	-$5,494
Effect of exchange rate	-$23	-$122	-$70
Change in cash and equivalents	-$2,986	$83	$2,961

Recent institutional transactions

Quarter	Shareholder	Change	Shares owned Shares	Value (in thousands USD)
2024 Q2	Dnb Asset Management As	+16.96%	526,909	$54,751,114
2024 Q2	Thurston, Springer, Miller, Herd & Titak, Inc	-81.63%	14,532	$1,509,943
2024 Q2	Massmutual Trust Co Fsb/adv	+54.08%	65,920	$6,849,747
2024 Q2	First Financial Bank - Trust Division	-5.49%	118,953	$12,360,410
2024 Q2	Appleton Partners Inc/ma	-13.69%	14,692	$1,527
2024 Q2	Woodstock Corp	+1.31%	130,691	$13,580,102
2024 Q2	Trust Co Of Toledo Na oh/	+1.26%	73,107	$7,596,548
2024 Q2	Moody National Bank Trust Division	+0.25%	18,941	$1,968,160
2024 Q2	General Partner	+0.50%	6,455	$670,739
2024 Q1	Winslow Capital Management	Opened	2,484,543	$282,393,157

Institutional shareholders

Shareholder	Stake	Shares owned Shares
Metatron Capital Sicav PLC	101.65%	1,768,286,969
Geode Capital Management	1.89%	32,853,400
Bank Of New York Mellon Corp	0.85%	14,757,476
Jpmorgan Chase & Co	0.81%	14,104,337
Ameriprise Financial Inc	0.58%	10,167,303
Flossbach Von Storch Ag	0.49%	8,573,419
Tiaa Cref Investment Management	0.49%	8,538,378
Amundi	0.41%	7,098,305
Ubs Asset Management Americas	0.40%	6,963,038
Parametric Portfolio Associates	0.39%	6,744,540

ABT Abbott Laboratories Compare

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

All time

Sign up for free

Recent Abbott Laboratories news Filter

Monday, 17 June 2024

Thursday, 6 June 2024

Friday, 31 May 2024

Thursday, 9 May 2024

Wednesday, 8 May 2024

Monday, 6 May 2024

Saturday, 13 April 2024

Friday, 12 April 2024

Thursday, 11 April 2024

Tuesday, 26 March 2024

Monday, 25 March 2024

Sunday, 24 March 2024

Friday, 22 March 2024

Thursday, 21 March 2024

Thursday, 14 March 2024

Monday, 11 March 2024

Wednesday, 6 March 2024

Wednesday, 28 February 2024

Wednesday, 21 February 2024

Tuesday, 20 February 2024

Wednesday, 14 February 2024

Saturday, 10 February 2024

Wednesday, 7 February 2024

Saturday, 3 February 2024

Friday, 2 February 2024

Thursday, 1 February 2024

Wednesday, 31 January 2024

Friday, 26 January 2024

Thursday, 25 January 2024

Wednesday, 24 January 2024

Saturday, 20 January 2024

Monday, 15 January 2024

Friday, 5 January 2024

Tuesday, 2 January 2024

Thursday, 28 December 2023

Tuesday, 19 December 2023

Monday, 18 December 2023

Thursday, 14 December 2023

Sunday, 10 December 2023

Friday, 8 December 2023

Thursday, 7 December 2023

Tuesday, 5 December 2023

Thursday, 30 November 2023

Sunday, 26 November 2023

Notable SEC filings of Abbott Laboratories All filings Last yearly filing Filter

Recent insiders trading at Abbott Laboratories Filter

Recent call transcripts of Abbott Laboratories

29,175 people own Abbott Laboratories on Robinhood

Overall analyst rating

Price target

Dividends

Abbott Laboratories dividend history

Abbott Laboratories executives

Comparable companies Compare more metrics Compare with other companies

Abbott Laboratories abbott.com/

Dividends

Abbott Laboratories dividend history

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

Income statement

Cash flows

Recent institutional transactions

Institutional shareholders

What symbols do you want to compare ABT with? Please separate symbols by ','

ABT

Abbott Laboratories

Compare

Recent Abbott Laboratories news

Filter

Notable SEC filings of Abbott Laboratories

All filings Last yearly filing Filter

Recent insiders trading at Abbott Laboratories

Filter

Comparable companies

Compare more metrics Compare with other companies

What symbols do you want to compare ABT with?
Please separate symbols by ','